Delaware
|
000-32501
|
33-0827593
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File
Number)
|
(I.R.S. Employer Identification Number)
|
□
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
□
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
□
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
(a)
|
On August 5, 2010, Cytori Therapeutics, Inc. (the "Company") held its Annual Meeting. The Company filed its definitive proxy statement for the proposals voted upon at the annual meeting with the Securities and Exchange Commission on April 30, 2010.
|
(b)
|
As of June 7, 2010, the record date for the annual meeting, 45,900,581 shares of the Company’s common stock were issued and outstanding. A quorum of 35,017,775 shares of common stock were present or represented at the annual meeting. The following items of business were voted upon by stockholders at the annual meeting:
|
1.
|
The following members of the Board of Directors were elected to serve until the 2011 annual meeting of stockholders and until their respective successors are elected and qualified. The voting results were as follows:
|
VOTES FOR
|
WITHHOLD AUTHORITY
|
|
Ronald D. Henriksen
|
14,409,278
|
320,058
|
Christopher K. Calhoun
|
14,553,720
|
175,616
|
Marc H. Hedrick, M.D.
|
14,561,047
|
168,289
|
Richard J. Hawkins
|
14,412,175
|
317,161
|
Paul W. Hawran
|
14,404,341
|
324,995
|
E. Carmack Holmes, M.D.
|
14,407,675
|
321,661
|
David M. Rickey
|
14,397,052
|
332,284
|
2.
|
Ratification of the selection of KPMG LLP as the independent public accountants for the Company for the fiscal year ending December 31, 2010. The voting results were as follows:
|
FOR
|
AGAINST
|
ABSTAIN
|
34,857,413
|
78,595
|
81,767
|
CYTORI THERAPEUTICS, INC.
|
|
Date: August 11, 2010
|
By: /s/ Mark E. Saad
|
Mark E. Saad
|
|
Chief Financial Officer
|